North America Transcatheter Heart Valves Market (2022-2033)

Increasing Prevalence of Valvular Heart Diseases

In North America, valvular heart diseases are a growing concern, largely due to aging populations and lifestyle-related cardiovascular risk factors such as high blood pressure, obesity, and diabetes. Degenerative conditions such as aortic stenosis and mitral regurgitation are being diagnosed more frequently in both the US and Canada, while rheumatic causes are rare but present in certain populations, including in parts of Mexico. Improved access to advanced diagnostic tools such as echocardiography, CT, and MRI enables earlier detection and better assessment of disease severity, increasing the number of patients who are eligible for intervention.

While surgical valve replacement has long been the standard treatment, it can be high-risk for older patients or those with other medical conditions. Transcatheter heart valve procedures offer a minimally invasive alternative that reduces hospital stay and procedural risk. Many specialized cardiac centers across the US and Canada have incorporated transcatheter programs into their structural heart disease services, increasing availability and adoption. Patients now have more treatment options, addressing previously unmet needs in high-risk groups.

Government healthcare programs, private insurance coverage, and advanced referral networks also contribute to early intervention and treatment access. Hospitals emphasize multidisciplinary heart teams, combining imaging, cardiology, and interventional expertise to improve outcomes. With rising disease prevalence and increasing patient awareness, transcatheter heart valves are becoming a critical solution in managing valvular heart disease in North America.

Growth in Mitral and Tricuspid Valve Applications

Although aortic valve procedures have historically dominated, there is a growing clinical focus on mitral and tricuspid valve disorders in North America. Advanced imaging technologies and expanded cardiology training have enabled physicians to diagnose better and treat these complex valve conditions. Hospitals in major centers such as New York, Toronto, and Mexico City are beginning to offer mitral and tricuspid transcatheter interventions, creating opportunities for both healthcare providers and device manufacturers.

Patients with mitral or tricuspid valve disease are often older or have comorbidities, making open-heart surgery riskier. Minimally invasive transcatheter therapies allow these patients to receive effective treatment with reduced recovery times and lower complication rates. Strong referral networks from smaller hospitals to larger cardiac centers improve patient access and awareness of these innovative procedures.

For device companies, this segment represents a clear growth opportunity. Providing physician training, procedural support, and clinical data can help expand the adoption of mitral and tricuspid interventions. As clinical confidence rises and patient acceptance grows, mitral and tricuspid valve applications are expected to become an important segment of the North America transcatheter heart valve market.

The "North America Transcatheter Heart Valves Market Size and Forecast (2022–2033)" report provides a detailed analysis of the market covering below areas:

• North America Transcatheter Heart Valves market size and forecast at regional and country levels for key market segments covered under the scope
• North America Transcatheter Heart Valves market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• North America Transcatheter Heart Valves market analysis covering key market trends, regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the North America Transcatheter Heart Valves market
• Detailed company profiles, including SWOT analysis

The geographical scope of the North America Transcatheter Heart Valves market report is divided into: The US, Canada and Mexico. The US held the largest share in 2024.

The US dominates the North America transcatheter heart valves market due to its advanced healthcare ecosystem, strong research culture, and leadership in medical technology innovation. Major hospitals and cardiac centers in cities such as Boston, Houston, and Cleveland have become recognized leaders in transcatheter valve interventions, offering patients access to cutting-edge technologies and highly skilled specialists. The country's leadership is reinforced by its active involvement in international and domestic clinical trials, which accelerates the introduction of new valve technologies and strengthen its role as a global hub for innovation.

Government support through Medicare and private insurance reimbursement has boosted adoption, making advanced therapies more accessible to patients. The US also benefits from a large pool of trained interventional cardiologists and surgeons, ensuring widespread availability of expertise across the country. Nonetheless, challenges remain. Rural populations often face limited access to specialized cardiac services, and the high cost of procedures continues to be a barrier for certain patient groups. Despite these limitations, the US remains the benchmark for transcatheter heart valve adoption in North America, setting the standard for innovation, accessibility, and regional growth in minimally invasive cardiac interventions.

• The report includes qualitative and quantitative data in the North America Transcatheter Heart Valves market across valve type, application, end user, and geography.
• The report starts with the key takeaways (chapter 2), highlighting the key trends and outlook of the North America Transcatheter Heart Valves market.
• Chapter 3 includes the research methodology of the study.
• Chapter 4 further includes ecosystem analysis.
• Chapter 5 highlights the major industry dynamics in the North America Transcatheter Heart Valves market, including factors that are driving the market, prevailing deterrents, potential opportunities, as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.
• Chapter 6 discusses the North America Transcatheter Heart Valves market scenario, in terms of historical market revenues, and forecast till the year 2033.
• Chapters 7 to 10 cover North America Transcatheter Heart Valves market segments by valve type, application, end user, and geography across the United States, Canada and Mexico. They cover the market revenue, forecast, and factors driving the market.
• Chapter 11 describes the competitive analysis along with the heat map analysis for the key players operating in the market.
• Chapter 12 describes the industry landscape analysis. It provides detailed descriptions of business activities such as market initiatives, new developments, mergers, and joint ventures globally, along with a competitive landscape.
• Chapter 13 provides detailed profiles of the major companies operating in the North America Transcatheter Heart Valves market. Companies have been profiled on the basis of their key facts, business descriptions, products, financial overview, SWOT analysis, and key developments.
• Chapter 14, i.e., the appendix, is inclusive of a brief overview of the company, list of abbreviations, and disclaimer.

The North America Transcatheter Heart Valves market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the North America transcatheter heart valves market are:

• In January 2026, Abbott Laboratories announced that its Navitor transcatheter aortic valve replacement (TAVR) system was linked to positive real‑world clinical outcomes in the US, with registry data showing favorable technical success and hemodynamic results for patients treated in routine practice following its earlier FDA approval.
• In May 2025, Edwards Lifesciences Corporation announced that the US Food and Drug Administration (FDA) approved its SAPIEN 3 transcatheter aortic valve replacement (TAVR) platform for use in asymptomatic severe aortic stenosis patients, the first FDA approval expanding TAVR to treat patients who do not yet show symptoms, potentially broadening the eligible patient population in the US.